Tablets film coated are shown to Glentset Advance for reduction of the symptoms connected with seasonal allergic rhinitis.

Structure

Active ingredients: montelukast, levocetirizine;

1 tablet, coated, contains montelukast of sodium is equivalent montelukastu10 to mg, a levotsetirizina of dihydrochloride of 5 mg;

Excipients: lactose, cellulose microcrystalline, double-base calcium phosphate waterless, sodium of a kroskarmelloz, hydroxypropyl cellulose, magnesium stearate, opadr yellow 1ZV52204 (gipromelloza, titan dioxide (E 171), macrogoal, iron oxide yellow (E172), polysorbate 80, iron oxide red (E172)).

Contraindication

Hypersensitivity to any of medicine components.

Route of administration

For adults and children is more senior than 15 years of a recomendoan a dose - 1 tablet a day, in the evening, irrespective of meal. Swallow of tablets entirely, without chewing. The course of treatment makes 14 days.

Feature of application

Pregnant

It is contraindicated.

Children

use Drug to children aged from 15 years.

Drivers

It is contraindicated.

Overdose

Montelukast. There are no specific recommendations about treatment of overdose of montelukast now. It was reported about cases of sharp overdose by montelukast during post-marketing observation and at conduct of clinical trials. To number of such messages messages about overdose cases at adults and children after application of such high doses, 1000 mg enter. Data of clinical and laboratory trials were agreed with safety profile for adults and children. In the majority of the registered cases of overdose of heavy side reactions it was not observed. The most frequent undesirable reactions were coordinated with a profile of safety of montelukast and included an abdominal pain, drowsiness, thirst, a headache, vomiting and psychomotor hyperactivity. It is unknown, montelukast by means of peritoneal dialysis or a hemodialysis is removed.

symptomatic treatment.

Levotsetirizin. It was reported about cases of overdose of a levotsetirizin. Symptoms of overdose can include drowsiness in adults, and children have at first a condition of excitement and concern with the subsequent development of drowsiness. The known specific antidote to a levotsetirizin does not exist. At overdose the symptomatic or maintenance therapy is recommended. Levotsetirizin is not brought at dialysis.

Side effects

Montelukast:

• Infection and parasitic diseases: upper respiratory tract infection.
• from digestive tract: diarrhea, nausea, vomiting.
• from skin and hypodermic cellulose: skin rashes.
• General frustration: fever.

Levotsetirizin:

• from nervous system: drowsiness, headache, increased fatigue, weakness, adynamy, spasms, paresthesias, dizziness, syncope, tremor, dysgeusia.
• from mentality: sleep disorder, excitement, hallucinations, depression, aggression, insomnia, suicide thoughts.
• from heart: tachycardia, tachycardia.
• from an organ of sight: disorder of vision, illegibility of sight.
• from organs of hearing and balance: vertigo.
• from a liver and biliary tract: hepatitis.
• from kidneys and an urinary system: dysuria, ischuria.
• from the immune system: hypersensitivity, including anaphylaxis.
• from the respiratory system, bodies of a thorax and mediastinum: short wind.
• from digestive tract: diarrhea, vomiting, a lock, dryness in a mouth, nausea, an abdominal pain.
• from skin and hypodermic fabrics: Quincke's disease, steady medicamentous rashes, itch, rash, small tortoiseshell.
• from a musculoskeletal system, connective tissue and bones: myalgia.

Interaction

Researches on levotsetirizin on interaction were not conducted.

Meal does not influence extent of absorption of medicine, but simultaneous consumption of food reduces absorption speed.

to Store

in the dry, protected from light place at a temperature not above 30 °C.

to Store

out of children's reach.

Expiration date - 2 years.